Journey Medical Corporation
NASDAQJourney Medical Corporation just reported Q1 2026 results that landed modestly ahead of revenue estimates — $15.96M versus the $15.95M consensus — with EPS of -$0.08, in line with expectations. Management signalled positive EBITDA for the rest of 2026 and plans to add up to five new sales professionals. On paper, a constructive print. Yet the stock closed Tuesday at $5.01, down 3.3%…
DERM short interest utilization hits 90.32%, near 52-week high of 99.63%.
Snapshot as of 30 Jun 2026
Journey Medical Corporation just reported Q1 2026 results that landed modestly ahead of revenue estimates — $15.96M versus the $15.95M consensus — with EPS of -$0.08, in line with expectations. Management signalled…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for DERM — free to start on ORTEX.
Sign up for free →Open DERM on ORTEXPulses are triggered by ORTEX's live data feeds. The full signal history, thresholds, and alerts are on ORTEX.
Live DERM data →